CONSUMER PACKAGE LEAFLET FOR VETERINARY MEDICINAL PRODUCT

The medicine is dispensed with a veterinarian's prescription only
For animal use only

1. NAME OF THE VETERINARY MEDICINAL PRODUCT, DOSAGE FORM AND STRENGTH

Bravecto Plus 112.5 mg/5.6 mg spot-on solution veterinary for Cats
Bravecto Plus 250 mg/12.5 mg spot-on solution veterinary for Cats
Bravecto Plus 500 mg/25 mg spot-on solution veterinary for Cats

Solution for topical (spot-on) use.

2. ACTIVE SUBSTANCE

Each 1 ml of solution contains 280 mg fluralaner and 14 mg moxidectin.

Each pipette contains:

BRAVECTO PLUS spot-on solution	**Pipette content (ml)**	**Fluralaner (mg)**	**Moxidectin (mg)**
for small cats 1.2 – 2.8 kg	0.4	112.5	5.6
for medium-sized cats >2.8 – 6.25 kg	0.89	250	12.5
for large cats >6.25 – 12.5 kg	1.79	500	25

Excipient(s):
Butylhydroxytoluene 1.07 mg/ml

A full list of excipients and allergens is detailed in section 13 – "Additional information".

3. WHAT IS THE MEDICINAL PRODUCT INTENDED FOR

For cats with, or at risk from, mixed parasitic infestations by ticks and fleas, gastrointestinal nematodes or heartworm. The veterinary medicinal product is exclusively indicated when use against ticks or fleas and one or more of the other target parasites is indicated at the same time.

For the treatment of tick and flea infestations in cats providing immediate and persistent flea (*Ctenocephalides felis*) and tick (*Ixodes ricinus*) killing activity for 12 weeks.
Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

For the treatment of infections with intestinal roundworm (4^{th} stage larvae, immature adults and adults of *Toxocara cati*) and hookworm (4^{th} stage larvae, immature adults and adults of *Ancylostoma tubaeforme*).

For the prevention of heartworm disease caused by *Dirofilaria immitis* for 8 weeks.

Therapeutic group: Antiparasitic.

4. CONTRAINDICATIONS

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

5. ADVERSE REACTIONS

Cats:

Common (1 to 10 animals / 100 animals treated):	Skin reactions at the application site (application site alopecia, flaking skin, application site reddening and application site pruritus)[#]
Uncommon (1 to 10 animals / 1,000 animals treated):	Dyspnoea (after licking the application site), Tachypnoea; Hypersalivation, Emesis, Haematemesis, Diarrhoea; Lethargy, Pyrexia; Mydriasis.
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Anorexia; Neurological disorders (e.g., tremor, ataxia).

[#] mild and transient

If you notice any side effects, even those not already listed in this package leaflet, or you think the medicine has not worked, please contact, in the first instance, your veterinarian. Side effects can be reported to the Ministry of Health by clicking on the link "Reporting side effects due to drug treatment" found on the Ministry of Health homepage (www.health.gov.il) that directs you to the online form for reporting side effects, or by entering the link:
https://sideeffects.health.gov.il

6. TARGET ANIMALS

Cats

7. ROUTE OF ADMINISTRATION AND DOSAGE

For topical (spot-on) use.

Bravecto Plus spot-on solution is available in three pipette sizes. The following table defines the size of pipette to be used according to the body weight of the cat (corresponding to a dose of 40-94 mg fluralaner/kg body weight and 2-4.7 mg moxidectin/kg body weight):

Weight of cat (kg)	**Pipette size to be used**
1.2 – 2.8	Bravecto Plus 112.5 mg + 5.6 mg spot-on solution for small cats
>2.8 – 6.25	Bravecto Plus 250 mg + 12.5 mg spot-on solution for medium-sized cats
>6.25 – 12.5	Bravecto Plus 500 mg + 25 mg spot-on solution for large cats

Within each weight band, the content of one whole pipette should be used.
For cats more than 12.5 kg, use a combination of two pipettes that most closely matches the body weight.

8. HOW TO USE THE PRODUCT

For topical use.
Method of administration

Step 1: Immediately before use, open the sachet and remove the pipette. Put on gloves. The pipette should be held by the base or by the upper rigid portion below the cap in an upright position (tip up) for opening it.
The twist-and-use cap should be rotated clockwise or counter clockwise one full turn. The cap will stay on the pipette; it is not possible to remove it. The pipette is open and ready for application when the breaking of the seal is felt.



Step 2: The cat should be standing or lying with its back horizontal for easy application. Place the pipette tip on the base of the skull of the cat.



Step 3: Squeeze the pipette gently and apply the entire contents directly to the cat's skin. The product should be applied on cats up to 6.25 kg body weight in one spot at the base of the skull and in two spots at the base of the skull on cats greater than 6.25 kg bodyweight.

Treatment
For the concurrent treatment of infections with the gastrointestinal nematodes *T. cati* and *A. tubaeforme*, a single dose of the product should be applied. The need for and frequency of re-treatment should be in accordance with the advice of the prescribing veterinarian and take into account the local epidemiological situation.
Where necessary, cats can be re-treated at 12-week intervals.

Cats in areas endemic for heartworm, or cats which have travelled to endemic areas, may be infected with adult heartworms. Therefore prior to application of Bravecto Plus for the concurrent prevention of infection with adult *D. immitis*, the advice provided in section 10 should be considered.

9. WITHDRAWAL PERIOD
Not applicable.

10. WARNINGS
- Special warnings regarding use of the medicine in the target animal treatment
  Ticks and fleas need to start feeding on the host to become exposed to fluralaner; therefore the risk of the transmission of parasite borne diseases cannot be excluded.

Cats in areas endemic for heartworm (or those which have travelled to endemic areas) may be infected with adult heartworms. No therapeutic effect against adult Dirofilaria immitis has been established. It is therefore recommended that animals of 6 months of age or older and living in areas where a vector exists, should be tested for existing adult heartworm infections before application of the veterinary medicinal product for the prevention of heartworm disease.
For the prevention of heartworm disease in cats that are only temporarily in endemic areas, the product should be applied before the first expected exposure to mosquitoes. The period between treatment and return from the endemic areas should not exceed 60 days.

For the treatment of infections with the gastrointestinal nematodes *T. cati* and *A. tubaeforme*, the need for, and the frequency of, re-treatment as well as the choice of the treatment (monosubstance or combination product) should be evaluated by the prescribing veterinarian.
Unnecessary use of antiparasitics or use deviating from the instructions may increase the resistance selection pressure and lead to reduced efficacy. The decision to use the veterinary medicinal product should be based on confirmation of the parasitic species and burden, or of the risk of infestation based on its epidemiological features, for each individual animal.
Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class under specific circumstances. Parasite control is recommended throughout the period of potential infestation risk.

The possibility that other animals in the same household can be a source of re-infection with fleas or gastrointestinal nematodes should be considered, and these should be treated as necessary with an appropriate veterinary medicinal product.

Avoid frequent swimming or shampooing the animal because the maintenance of effectiveness of the product in these cases has not been tested.

- <u>Special warnings relating to the safety of use of the medicine in animals</u>
  Care should be taken to avoid contact with the eyes of the animal.
  Do not use directly on skin lesions.
  In the absence of available data, treatment of kittens less than 9 weeks of age and cats less than 1.2 kg bodyweight is not recommended.
  Treatment of male breeding animals is not recommended.
  This product is for topical use and should not be administered orally.
  Oral uptake of the product at the maximum recommended dose of 93 mg fluralaner + 4.65 mg moxidectin/kg body weight induced some self-limiting salivation or single incidences of vomiting immediately after administration.
  It is important to apply the dose as indicated to prevent the animal from licking and ingesting the product (see sections 5 and 8).
  Do not allow recently treated animals to groom each other.
  Do not allow treated animals to come into contact with untreated animals until the application site is dry.

- Special warnings relating to the safety of the person administering the medicinal product
  Contact with the product should be avoided and disposable protective gloves must be worn when handling the product for the following reasons:
  Hypersensitivity reactions have been reported in a small number of people, which can potentially be serious.
  Persons with a hypersensitivity to fluralaner or to any of the excipients should avoid any exposure to the product.
  The product binds to skin and may also bind to surfaces after spillage of the product.
  Skin rashes, tingling or numbness have been reported in a small number of individuals after skin contact.
  If skin contact does occur, wash the affected area immediately with soap and water. In some cases, soap and water are not sufficient to remove the product spilled on the fingers.
  Contact with the product may also occur when handling the treated animal.
  Make sure that your animal's application site is no longer noticeable before resuming contact with the site of application. This includes cuddling the animal and sharing a bed with the animal. It takes up to 48 hours for the application site to become dry but it will be noticeable for longer.
  If skin reactions occur, consult a physician and show them the product packaging.
  People with a sensitive skin or known allergy in general e.g. to other veterinary medicinal products of this type should handle the veterinary medicinal product as well as treated animals with caution.
  This product can cause eye irritation. In case of contact with the eyes, immediately rinse thoroughly with water.
  This product is harmful after ingestion. Keep the product in the original packaging until use, in order to prevent children from getting direct access to the product. A used pipette should immediately be disposed of. In case of accidental ingestion, seek medical advice and show the package leaflet or the label to the physician.
  The product is highly flammable. Keep away from heat, sparks, open flame or other sources of ignition.
  In case of spillage onto surface (for example table or floor), remove excess product using paper tissue and clean the area with detergent.

- Pregnancy and lactation of the treated animal
  The safety of the veterinary medicinal product has not been established in pregnant or lactating animals and therefore use in such animals is not recommended.

- Interactions with other medicinal products and other forms of interactions
  Macrocyclic lactones including moxidectin have been shown to be substrates for p-glycoprotein. Therefore, during treatment with the product, other products that can inhibit p-glycoprotein (e.g. cyclosporine, ketoconazole, spinosad, verapamil) should only be used concomitantly according to the benefit-risk assessment of the responsible veterinarian.

- Overdose
  No adverse reactions were observed following topical administration to kittens aged 9-13 weeks and weighing 0.9-1.9 kg treated with overdoses of up to 5 times the maximum recommended dose (93 mg fluralaner + 4.65 mg moxidectin, 279 mg fluralaner + 13.95

mg moxidectin and 465 mg fluralaner + 23.25 mg moxidectin/kg body weight) on three occasions at shorter intervals than recommended (8-week intervals).

- Incompatibility
  None known.

11. STORAGE INSTRUCTIONS

- Avoid poisoning! This medicinal product and any other medicinal products must be stored in a closed place out of the reach and sight of children and/or infants, in order to avoid poisoning.
- Do not use this medicinal product after the expiry date (Exp. Date) that appears on the packaging. The expiry date refers to the last day of that month.
- Storage conditions
  Store below 25ºC.
  The pipette should be kept in the sachet to prevent solvent loss or moisture uptake. The sachet should only be opened immediately prior to use.

12. INSTRUCTIONS REGARDING DISPOSAL OF THE MEDICINAL PRODUCT/REMNANTS OF THE MEDICINAL PRODUCT AFTER USE

Any unused veterinary medicinal product or waste materials derived from use of the veterinary medicinal product should be disposed of as toxic waste, do not throw to sewer.
Ask your veterinarian or pharmacist how to dispose of medicines no longer required.
These measures should help to protect the environment.
Do not allow the product to enter water courses as this may be dangerous for fish and other aquatic organisms.

13. ADDITIONAL INFORMATION

- In addition to the active ingredients the medicine also contains:
  Dimethylacetamide, Glycofurol, Diethyltoluamide, Acetone, Butylhydroxytoluene.
- What the medicine looks like and contents of the package:
  Clear colourless to yellow solution.
  Pipette made of laminated aluminium/polypropylene foil, closed with HDPE cap and packed in a laminated aluminium foil sachet.
- Package size:
  Each cardboard box contains 1 or 2 pipettes. Not all pack sizes may be marketed.
- The product contributes towards the control of environmental flea populations in areas to which treated cats have access.
  The onset of effect (killing effect) for ticks (I. ricinus) and fleas (C. felis) is within 48 hours after treatment.
- Registration holder and address:
  Intervet Israel Ltd., Industrial zone Nave Ne'eman, Hod-Hasharon 45240
- Manufacturer and address:
  Intervet International B.V. (MSD Animal Health)
  Boxmeer, The Netherlands.

- Revised in June 2024.

- Medicinal product registration number at the National Medicines Registry of the Ministry of Health:
  Bravecto Plus 112.5 mg/5.6 mg spot-on solution veterinary for Cats 168-79-35936-00
  Bravecto Plus 250 mg/12.5 mg spot-on solution veterinary for Cats 168-80-35937-00
  Bravecto Plus 500 mg/25 mg spot-on solution veterinary for Cats 168-81-35938-00